Home » Topics » BioWorld Science

BioWorld Science
RSS

Meiji Seika Pharma describes new PDE4 inhibitors

Jan. 20, 2020

AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators

Jan. 20, 2020

Single transcription factor enables chronic toxoplasma infection

Jan. 20, 2020

B cells help T cells succeed during checkpoint blockade

Jan. 20, 2020

Roche discloses new EGFR mutant inhibitors

Jan. 20, 2020

Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors

Jan. 20, 2020

ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy

Jan. 20, 2020

OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML

Jan. 20, 2020

Novel muraminomicin derivatives with potent activity in MRSA infection models

Jan. 20, 2020

Sanofi initiates phase III study of SAR-408701 in CEACAM5-positive metastatic nonsquamous NSCLC

Jan. 20, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....